H
Hans Theodor Eich
Researcher at University of Cologne
Publications - 230
Citations - 6423
Hans Theodor Eich is an academic researcher from University of Cologne. The author has contributed to research in topics: Medicine & Radiation therapy. The author has an hindex of 36, co-authored 169 publications receiving 5242 citations.
Papers
More filters
Journal ArticleDOI
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
Andreas Engert,Annette Plütschow,Hans Theodor Eich,Andreas Lohri,Bernd Dörken,Peter Borchmann,Bernhard Berger,Richard Greil,Kay C. Willborn,Martin Wilhelm,Jürgen Debus,Michael J. Eble,Martin Sökler,A. D. Ho,Andreas Rank,Arnold Ganser,Lorenz Trümper,Carsten Bokemeyer,Hartmut Kirchner,Jörg Schubert,Zdenek Kral,Michael Fuchs,Hans Konrad Müller-Hermelink,Rolf-Peter Müller,Volker Diehl +24 more
TL;DR: In patients with early-stage Hodgkin's lymphoma and a favorable prognosis, treatment with two cycles of ABVD followed by 20 Gy of involved-field radiation therapy is as effective as, and less toxic than, four cycles ofABVD following by 30 Gy ofinvolved- field radiation therapy.
Journal ArticleDOI
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
Andreas Engert,Heinz Haverkamp,Carsten Kobe,Jana Markova,Christoph Renner,A. D. Ho,Josée M. Zijlstra,Zdenek Kral,Michael Fuchs,Michael Hallek,Lothar Kanz,Hartmut Döhner,Bernd Dörken,Nicole Engel,Max S. Topp,Susanne Klutmann,Holger Amthauer,Andreas Bockisch,Regine Kluge,Clemens Kratochwil,Otmar Schober,Richard Greil,Reinhard Andreesen,Michael Kneba,Michael Pfreundschuh,Harald Stein,Hans Theodor Eich,Rolf-Peter Müller,Markus Dietlein,Peter Borchmann,Volker Diehl +30 more
TL;DR: Treatment with six cycles of BEACOPP(escalated) followed by PET-guided radiotherapy was more effective in terms of freedom from treatment failure and less toxic than eight cycles of the same chemotherapy regimen, and should be the treatment of choice for advanced stage Hodgkin's lymphoma.
Journal ArticleDOI
Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial
Hans Theodor Eich,Volker Diehl,Helen Görgen,Thomas Pabst,Jana Markova,Jürgen Debus,Anthony D. Ho,Bernd Dörken,Andreas Rank,Anca-Ligia Grosu,Thomas Wiegel,Johann H. Karstens,Richard Greil,Normann Willich,Heinz Schmidberger,Hartmut Döhner,Peter Borchmann,Hans Konrad Müller-Hermelink,Rolf-Peter Müller,Andreas Engert +19 more
TL;DR: Moderate dose escalation using BEACOPP(baseline) did not significantly improve outcome in early unfavorable HL, and four cycles of ABVD should be followed by 30 Gy of IFRT.
Journal ArticleDOI
Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial
Bastian von Tresckow,Annette Plütschow,Michael Fuchs,Beate Klimm,Jana Markova,Andreas Lohri,Zdenek Kral,Richard Greil,Max S. Topp,Julia Meissner,Josée M. Zijlstra,Martin Soekler,Harald Stein,Hans Theodor Eich,Rolf P. Mueller,Volker Diehl,Peter Borchmann,Andreas Engert +17 more
TL;DR: Intensified chemotherapy with two cycles of BEACOPP escalated followed by three cycles of ABVD followed by IFRT significantly improves tumor control in patients with early unfavorable HL.
Journal ArticleDOI
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
Peter Borchmann,Helen Goergen,Carsten Kobe,Andreas Lohri,Richard Greil,Dennis A. Eichenauer,Josée M. Zijlstra,Jana Markova,Julia Meissner,Michaela Feuring-Buske,Andreas Hüttmann,Judith Dierlamm,Martin Soekler,Hans Joachim Beck,Wolfgang Willenbacher,Wolf-Dieter Ludwig,Thomas Pabst,Max S. Topp,Felicitas Hitz,Martin Bentz,Ulrich Keller,Dagmar Kühnhardt,Helmut Ostermann,Norbert Schmitz,Bernd Hertenstein,Walter E. Aulitzky,Georg Maschmeyer,Tom Vieler,Hans Theodor Eich,Christian Baues,Harald Stein,Michael Fuchs,Georg Kuhnert,Volker Diehl,Markus Dietlein,Andreas Engert +35 more
TL;DR: This open-label, randomised, parallel-group phase 3 trial investigated whether metabolic response determined by PET after two cycles of standard regimen eBEACOPP (PET-2) would allow adaption of treatment intensity, increasing it for PET-2-positive patients and reducing it forPET- 2-negative patients and showed non-inferiority in the 5-year progression-free survival estimates.